Hong Kong Stock Exchange news | Kangfang Biology (09926.HK) rises by more than 3% again as Cadunilimab obtains FDA approval to conduct Phase III clinical trials for gastric cancer therapy.

Zhitong Financial Network APP has learned that Kangfang Biotech (09926.HK) has risen by more than 3% again. As of the time of publication, it has risen by 3.83% to HK$121.9, with a turnover of HK$271 million.